Georgi Kamburov

Interest in Nuvilex, Inc. (OTCMKTS:NVLX) Dissipates

by Georgi Kamburov September 4, 2013
5NVLXchart.pngIt seems that the law of diminishing returns has finally caught up with the stock of Nuvilex, Inc. (OTCMKTS:NVLX) who had four red session out of the last five. The reason traders might have had enough with the company surely has something to do with the truly massive promotional campaign that has been going on non-stop for the past couple of months.

And although the money passed around may not put them among the likes of Alkaline Water Co, Inc. (OTCBB:WTER, WTER message board) who are allegedly backed by a pump with a $3 million budget, the sheer amount of email alerts and PR articles issued for NVLX is astounding. We are only September 4 and we have received close to 10 different touts which more than likely signals that the promo is far from reaching its end.

03SNETchart.pngThe latest addition to the myriad of previous newsletters are BreakingBulls, MarqueePennyStocks and PsychoPennyStocks, all affiliates of MHC Inc. They disclosed receiving $15 000 as compensation for their services. They bagged the exact same amount when they were involved with SourcingLink.net, Inc. (OTCMKTS:SNET). The results speak for themselves.

Other then that the paid researchers OTCJournal, Goldman Small Cap Research and Stock Market Media Group are still ensuring that there is a new article about NVLX almost daily. The nearly record amount of PR news led to some amusing headlines in the likes of "The stars align for Nuvilex" which of course didn't have a sliver of substantial information in it.

The two articles published on SeekingAlpha made praising the company even harder by listing all the numerous red flags surrounding it. The frequent change in business direction, the eagerness to join the medical marijuana industry during its boom in February with no real follow-up development, the still ongoing pump campaign are all serious enough issues to justify doing your own due diligence.

For now the saving grace for NVLX is its cell encapsulation technology and the much talked about Phase III pancreatic cancer trial that is planned for ... sometime in the future. And by saying much talked about we mean all the various paid materials, in the actual annual report filed on July 29 such a thing isn't even mentioned.

Comments 0

Type the characters that you see in the box (5 characters).